Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis
- 20 May 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (19) , 2428-2434
- https://doi.org/10.1161/01.cir.0000066907.83923.32
Abstract
Background— Patients with giant-cell arteritis (GCA) who develop a strong acute-phase response are at low risk of disease-related ischemic events. Methods and Results— To assess the potential prote...Keywords
This publication has 30 references indexed in Scilit:
- A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant‐cell arteritisArthritis Care & Research, 2002
- In vivoactivation of JAK2/STAT‐3 pathway during angiogenesis induced by GM‐CSFThe FASEB Journal, 2001
- Preparation of Endothelial CellsCurrent Protocols in Cell Biology, 1998
- Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte RecruitmentPublished by Elsevier ,1997
- Signaling through CD50 (ICAM‐3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in β1 and β2 integrin functionEuropean Journal of Immunology, 1994
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994
- The acute phase responseImmunology Today, 1994
- Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.Journal of Clinical Investigation, 1993
- Extension of the Life-Span of Human Endothelial Cells by an Interleukin-1αAntisense OligomerScience, 1990
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988